Dynport Vaccine Company LLC

Frederick, MD DVC Segment Part of General Dynamics Information Technology, Inc.

UEI
LXNEGTYDR755
CAGE
1GFE1
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

FY2025 rankings

Its parent company, General Dynamics Corporation, ranks:

Self-certified in SAM.gov
  • For Profit Organization
  • Limited Liability Company
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
  • Headquarters Parent General Dynamics Information Technology, Inc. · Falls Church, VA SMNWM6HN79X5
    • DVC Segment
SAM.gov registration date
Physical address
12 W Church St #234, Frederick, MD 21701, USA
Website
dxc.com
Founded
2017
Employees
100K+
Estimated annual revenue
$10B+
Industry
  1. Information Technology
  2. Software & Services
  3. IT Services
  4. Data Processing & Outsourced Services
SIC code
73 Business Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $510,415
FY2025 -$6,063,528
FY2024 -$97,364,978
FY2023 $5,642,157

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Department of the Army $327,108
2 Department of Health and Human Services $177,220
3 Defense Health Agency $6,087

Contract vehicles

Expired vehicles (3)

Contract awards

Latest 5 listed here. See the rest on GovTribe.

Grant awards

Award Agency Obligated Awarded
Fast-track production of a heptavalent botulinum vaccine U01AI056514 National Institutes of Health $288,859

Similar vendors

About the company

Dynport Vaccine Company LLC DVC Segment Division is a subsidiary of General Dynamics Corp. that provides a range of research, development, manufacturing, and testing services to support biopharmaceutical products targeting infectious diseases.

Through past federal contracts, Dynport has provided preclinical development, clinical trials, diagnostic testing, vaccine stability evaluations, and cGMP production services in support of therapeutics and vaccines for emerging infectious diseases. Major customers include NIH, HHS, and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. Prime contract awards have funded process development, assay validation, pilot manufacturing, Phase I trials, and stability testing of vaccine candidates over 1-5 year periods. Subcontracts have supported clinical trials and CGMP cell bank production. Most awards utilize firm fixed price or cost plus fixed fee structures without set asides. Places of performance are centered at Dynport's Maryland-based locations.

Dynport holds several infectious disease-focused IDVs as a prime contractor, most notably the $30 million Preclinical Services for Biopharmaceutical Product Development contract from NIH-NIAID. This single-award IDIQ covers process development, assay validation, CGMP production, and regulatory documentation to support candidate vaccines and therapies from early inception through preclinical advancement. Dynport also holds the $36 million Diagnostic Pre-Clinical Services Program contract, which funds development processes needed to bring candidate infectious disease diagnostics to market. Additionally, Dynport is one of multiple awardees under the $346 million Early Phase Clinical Trial Units IDIQ, which has funded Phase I trial services under cost plus fixed fee delivery orders to date.

Quick answers

Is Dynport Vaccine Company LLC registered in SAM.gov?

Yes. Dynport Vaccine Company LLC's SAM.gov registration is active through June 23, 2027.

Which contract vehicles does Dynport Vaccine Company LLC hold?

Dynport Vaccine Company LLC holds a place on 4 federal contract vehicles, including EPCTU.

How does Dynport Vaccine Company LLC rank among federal contractors?

Dynport Vaccine Company LLC's parent company, General Dynamics Corporation, ranked #1 in NAICS 54, #3 at the Department of Defense and #8 in PSC AC13 in FY2025.

What is Dynport Vaccine Company LLC's most recent federal award?

Dynport Vaccine Company LLC's most recent federal contract award is Diagnostic pre-clinical services program -IDIQ - dynport (75N93023F00003), from National Institute of Allergy and Infectious Diseases (NIH), on June 20, 2023.

On GovTribe

See Dynport Vaccine Company LLC's full federal record

  • Federal contract awards
  • IDV awards
  • Contract vehicles
  • Federal grant awards
  • Subcontracting relationships
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors